Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
279.00
+0.62 (0.22%)
At close: May 13, 2025, 4:00 PM
278.99
-0.01 (0.00%)
Pre-market: May 14, 2025, 9:03 AM EDT
Cencora Revenue
Cencora had revenue of $75.45B in the quarter ending March 31, 2025, with 10.29% growth. This brings the company's revenue in the last twelve months to $310.23B, up 12.18% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$310.23B
Revenue Growth
+12.18%
P/S Ratio
0.18
Revenue / Employee
$6,744,178
Employees
46,000
Market Cap
54.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
COR News
- 6 days ago - Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings - Benzinga
- 6 days ago - Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
- 7 days ago - Cencora Reports Fiscal 2025 Second Quarter Results - Business Wire
- 5 weeks ago - 3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock - Barrons
- 6 weeks ago - These 15 stocks are the most profitable companies in the S&P 500 - Market Watch
- 6 weeks ago - Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release - Business Wire
- 2 months ago - Cencora: Higher Potential Returns After Reduced Walgreens Stake - Seeking Alpha